Log in to your Inderes Free account to see all free content on this page.
Cantargia
4.03 SEK
-3.82 %
1,288 following
CANTA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-3.82 %
-14.89 %
-3.70 %
-3.70 %
+43.93 %
+181.82 %
-40.52 %
-84.53 %
-42.97 %
Cantargia operates in the pharmaceutical industry and focuses on the development of treatments for cancer and inflammatory diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business is global with a primary presence in Europe and North America. Cantargia was founded in 2009 and is headquartered in Lund, Sweden.
Read moreMarket cap
1B SEK
Turnover
3.87M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
19.5.
2026
Interim report Q1'26
21.5.
2026
General meeting '26
19.8.
2026
Interim report Q2'26
All
Webcasts
Press releases
3rd party
ShowingAll content types
Cantargia to participate at Van Lanschot Kempen’s Life Sciences Conference
Redeye: Cantargia (Q4 Review): New Developments in PDAC
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
